Compare Saniona AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 1,952 Million (Small Cap)
4.00
NA
0.00%
-0.91
44.82%
3.07
Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Dec 2025)
Net Profit:
-42 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-46.6%
0%
-46.6%
6 Months
-9.45%
0%
-9.45%
1 Year
70.58%
0%
70.58%
2 Years
650.56%
0%
650.56%
3 Years
166.56%
0%
166.56%
4 Years
418.4%
0%
418.4%
5 Years
-17.61%
0%
-17.61%
Saniona AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
176.36%
EBIT Growth (5y)
46.99%
EBIT to Interest (avg)
-8.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.77
Tax Ratio
7.99%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
17.87%
Valuation key factors
Factor
Value
P/E Ratio
4
Industry P/E
Price to Book Value
3.04
EV to EBIT
2.33
EV to EBITDA
2.31
EV to Capital Employed
83.64
EV to Sales
1.91
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3582.15%
ROE (Latest)
83.18%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
4.60
410.70
-98.88%
Operating Profit (PBDIT) excl Other Income
-44.60
362.40
-112.31%
Interest
0.10
3.00
-96.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-41.70
329.60
-112.65%
Operating Profit Margin (Excl OI)
-10,089.30%
878.10%
-1,096.74%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -98.88% vs 4,316.13% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -112.65% vs 1,584.68% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
434.40
334.70
29.79%
Operating Profit (PBDIT) excl Other Income
281.50
246.80
14.06%
Interest
1.70
38.90
-95.63%
Exceptional Items
33.70
0.00
Consolidate Net Profit
284.70
188.70
50.87%
Operating Profit Margin (Excl OI)
632.40%
714.50%
-8.21%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 29.79% vs 1,892.26% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 50.87% vs 296.97% in Dec 2024
About Saniona AB 
Saniona AB
Pharmaceuticals & Biotechnology
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.






